Table 3.
Cox proportional hazards regression analysis of 5-year distant disease-free survival according to St Gallen Molecular subtypes with luminal A as reference group
|
A. Univariable analysis | ||||||
|---|---|---|---|---|---|---|
| |
Primary tumour |
Lymph node metastases |
||||
| Frequency N (%) | HR (95% CI) | p -value | FrequencyN (%) | HR (95% CI) | p -value | |
|
luminal A |
45 (53) |
1.0 |
|
38 (45) |
1.0 |
|
|
luminal B |
17 (20) |
2.8 (0.94-8.4) |
0.064 |
23 (27) |
3.1(1.0-9.5) |
0.048 |
|
HER2-positive |
11 (13) |
4.5 (1.4-14) |
0.011 |
11 (13) |
7.3 (2.2-24) |
0.001 |
|
Triple negative |
12 (14) |
5.9 (2.1-17) |
0.001 |
13 (15) |
4.6 (1.4-15) |
0.011 |
|
B. Multivariable analysis | ||||||
| |
Primary tumour
1
|
Lymph node metastases
1
|
||||
| |
Frequency
N
(%) |
HR (95% CI) |
p
-value |
FrequencyN (%) |
HR (95% CI) |
p
-value |
|
luminal A |
45 (53) |
1.0 |
|
38 (45) |
1.0 |
|
|
luminal B |
17 (20) |
2.9 (0.96-8.8) |
0.059 |
23 (27) |
2.9 (0.92-9.0) |
0.070 |
|
HER2-positive |
11 (13) |
3.1 (0.94-10) |
0.063 |
11 (13) |
4.8 (1.3-17) |
0.016 |
| Triple negative | 12 (14) | 4.6 (1.6-13) | 0.006 | 13 (15) | 3.9 (1.2-13) | 0.029 |
1Adjusted for calendar-period (year at time of operation), age (years) and study regime (postmenopausal versus premenopausal study).
Abbreviations: HER2 human epidermal growth factor receptor 2, HR hazard ratio, CI confidence interval, N number of patients, percentages are given within parenthesis.